TITLE

UK Biotech Company Leading Fight to Cure E. coli

PUB. DATE
August 2011
SOURCE
Worldwide Biotech;Aug2011, Vol. 23 Issue 8, p8
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article reports that as of August 2011, Phico Therapeutics is the leading company for the treatment of fatal bacteria. Phico is a company based in Cambridge, England, and has developed a new antibiotic technology called SASPject. They have also raised about 1 million British pounds in order to develop the technology further. With this method, Phico believes it can better treat conditions like methicillin-resistant staphylococcus aureus (MRSA) and escherichia coli.
ACCESSION #
63617961

 

Related Articles

  • ICAAC Roundup.  // BioWorld Today;9/15/2009, Vol. 20 Issue 177, p4 

    The article reports on the preclinical data presented by Phico Therapeutics at the ongoing Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in the U.S. for its antibiotic SASPject PTI.2. Based on the data, the compound is effective against methicillin-resistant...

  • Impact of the agr Quorum-Sensing System on Adherence to Polystyrene in Staphylococcus aureus. Cuong Vuong; Saenz, Henri L.; Gotz, Friedrich; Otto, Michael // Journal of Infectious Diseases;12/1/2000, Vol. 182 Issue 6 

    Biofilm formation by Staphylococcus aureus is a serious problem in nosocomial infections. There are great differences in the capacity of S. aureus to express biofilms, but the reasons are unknown. In all, 105 S. aureus strains were tested for a correlation between the agr quorum-sensing system...

  • Norway Stops Superbug.  // Current Science;4/16/2010, Vol. 95 Issue 15, p14 

    The article reports on the move of the Norwegian government to cut back on too much use of antibiotics for the treatment of Staphylococcus aureus infections (MRSA) among patients which have yielded into positive results and reduced the number of people infected by the bacteria.

  • Community-associated methicillin-resistant Staphylococcus aureus: prevalence in skin and soft tissue infections at emergency departments in the Greater Toronto Area and associated risk factors. Adam, Heather J.; Allen, Vanessa G.; Currie, Andrea; McGeer, Allison J.; Simor, Andrew E.; Richardson, Susan E.; Louie, Lisa; Willey, Barbara; Rutledge, Tim; Lee, Jacques; Goldman, Ran D.; Somers, Andrea; Ellis, Paul; Sarabia, Alicia; Rizos, John; Borgundvaag, Bjug; Katz, Kevin C. // CJEM: Canadian Journal of Emergency Medicine;Sep2009, Vol. 11 Issue 5, p439 

    Objective: Community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA), which is caused primarily by the Canadian methicillin-resistant Staphylococcus aureus-10 (CMRSA-10) strain (also known as the USA300 strain) has emerged rapidly in the United States and is now emerging in...

  • Emergence, Mechanism, and Clinical Implications of Reduced Glycopeptide Susceptibility in Staphylococcus aureus. Geisel, R.; Schmitz, F.J.; Fluit, A.C.; Labischinski, H. // European Journal of Clinical Microbiology & Infectious Diseases;Oct2001, Vol. 20 Issue 10, p685 

    In order to understand the mechanism(s) of the resistance/reduced susceptibility of Staphylococcus aureus to glycopeptide antibiotics, the current data on the modes of action of glycopeptides were reviewed. In addition, the different test systems for detecting vancomycin resistance and the...

  • Staphylococcus aureus and vancomycin: the sequel. Karchmer, Adolf W.; Karchmer, A W // Annals of Internal Medicine;11/1/91, Vol. 115 Issue 9, p739 

    Editorial. Discusses research on the use of vancomycin in the treatment of Staphylococcus aureus (S. aureus) infections in the U.S. as of November 1991. Types of antibiotics used in the treatment of S. aureus; Advantages of using vancomycin; Concerns on the resistance of S. aureus to vancomycin.

  • EPIDEMIOLOGY AND ANTIBIOTIC TREATMENT OF INFECTIVE ENDOCARDITIS: AN UPDATE. Hoen, Bruno // Heart;Nov2006, Vol. 92 Issue 11, p1694 

    The article discusses the epidemiological profile and antibiotic treatment of patients with infective endocarditis. Staphylococcus aureus is the main cause of infective endocarditis. The intravenous route for antibiotic administration is the best for treating infective endocarditis because it...

  • Staphylococcus aureus Endocarditis with Multivalvular Involvement Secondary to an Atrial Septal Defect. Daruwalla, Vistasp Jimmy; Sagi, Jahnavi; Tahir, Hassan; Penumetsa, Srikanth // Case Reports in Cardiology;2/16/2016, p1 

    Infective endocarditis is usually diagnosed using modified Duke’s criteria. Our patient had a subacute presentation and a low suspicion for endocarditis during admission, unfortunately leading to her death. Despite advances in diagnostic and therapeutic measures including antibiotic...

  • Assessment of risk factors in the development of MRSA infection at Gülhane Military Medical Faculty Education Hospital and the role of antibiotic use on the development of MRSA infection. Gunal, E.; Besirbellioglu, B. A.; Ersoz, F.; Avci, I. Y.; Eyigun, C. P. // BMC Proceedings;Jan2011 Supplement 6, Vol. 5, pP14 

    An abstract of the article "Assessment of risk factors in the development of MRSA infection at Guelhane Military Medical Faculty Education Hospital and the role of antibiotic use on the development of MRSA infection," by E. Gunal, F. Ersoz and C. P. Eyigun is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics